MK-677 Side Effects: What the Clinical Data Shows
MK-677 (Ibutamoren)
40% increase
Fasting blood glucose rose by approximately 0.3 mmol/L in healthy older adults after 12 months of daily MK-677, with some participants meeting criteria for impaired fasting glucose.
Nass et al., Annals of Internal Medicine, 2008
Nass et al., Annals of Internal Medicine, 2008
View as imageMK-677 (ibutamoren) is one of the most widely discussed compounds in the growth hormone space, largely because it is orally active and does not require injection. It works by mimicking ghrelin at the GHS-R1a receptor, stimulating pulsatile growth hormone release and raising IGF-1 levels. But the same mechanism that makes it effective also drives its three most consistent side effects: increased appetite, water retention, and worsened insulin sensitivity. These are not rare adverse events. They appeared across every major clinical trial, from the earliest studies in the 1990s through the longest randomized controlled trial published in 2008. Understanding these effects requires looking at the actual trial data, not forum anecdotes.
Key Takeaways
- In the 12-month Nass et al. (2008) trial of 65 healthy older adults, MK-677 increased fat-free mass by 1.1 kg but worsened fasting glucose by approximately 0.3 mmol/L and did not improve functional strength[1]
- Svensson et al. (1998) documented that 2-month MK-677 treatment in obese subjects raised fasting glucose from 4.8 to 5.2 mmol/L and increased fasting insulin by 26%, indicating reduced insulin sensitivity[2]
- Appetite stimulation is a direct pharmacological effect of GHS-R1a activation, not a side effect that can be separated from the drug's mechanism of action[3]
- The hip fracture recovery trial (Adunsky et al., 2011) found no functional benefit from MK-677 despite raising IGF-1 levels, and was stopped early due to congestive heart failure signals in treated patients[4]
- Sigalos and Pastuszak (2018) reviewed the safety profile of growth hormone secretagogues and concluded that MK-677 consistently raises GH and IGF-1 but with metabolic side effects that limit its clinical utility[5]
- A 2022 human study confirmed that recreational MK-677 use impacted body composition, circulating biomarkers, and hormonal profiles consistent with GH/IGF-1 axis activation[6]
Insulin resistance and glucose dysregulation
The most clinically concerning side effect of MK-677 is its impact on glucose metabolism. This effect has been documented in every major trial.
Nass et al. (2008) conducted the longest and most rigorous MK-677 study: a 12-month randomized, double-blind, placebo-controlled trial in 65 healthy adults aged 60-81. MK-677 at 25 mg daily increased GH and IGF-1 levels to those of young adults. But fasting blood glucose increased by approximately 0.3 mmol/L on average, with some participants developing impaired fasting glucose (100-125 mg/dL). Fasting insulin levels also rose, indicating that the body was producing more insulin to manage the higher glucose, a hallmark of insulin resistance.[1]
Svensson et al. (1998) saw the same pattern in a different population. In obese subjects treated with MK-677 for 2 months, fasting glucose rose from 4.8 to 5.2 mmol/L (an 8% increase) and fasting insulin rose by 26%. Insulin sensitivity deteriorated measurably. These changes occurred despite the subjects simultaneously gaining fat-free mass and losing visceral fat.[2]
The mechanism is straightforward. Growth hormone is a counter-regulatory hormone to insulin. It promotes lipolysis (fat breakdown) and gluconeogenesis (glucose production), both of which raise blood sugar. When MK-677 elevates GH levels for 24 hours per day, every day, the sustained anti-insulin effects accumulate. This is the same metabolic profile seen in acromegaly (excess GH from a pituitary tumor), where insulin resistance and type 2 diabetes are common complications.
The Alzheimer's disease trial by Sevigny et al. (2008) provided additional glucose data. In that 12-month study, MK-677 raised HbA1c levels in treated patients, with several diabetic participants requiring adjustments to their diabetes medications. The trial found no benefit for AD progression.[7]
Water retention and edema
Fluid retention is the most immediately noticeable side effect of MK-677. Growth hormone promotes sodium and water retention through direct effects on the kidneys, and MK-677's sustained GH elevation produces clinically apparent fluid shifts.
In the Nass et al. (2008) trial, transient lower extremity edema was reported in the first few weeks of treatment. Most cases resolved spontaneously without dose adjustment, but the fluid retention was sufficient to affect body weight measurements and required accounting for in the body composition analysis.[1]
The hip fracture recovery trial (Adunsky et al., 2011) revealed a more serious manifestation. This multicenter, randomized, placebo-controlled trial tested MK-677 in elderly patients recovering from hip fracture. The trial was terminated early, in part because of signals for congestive heart failure (CHF) in MK-677-treated patients. Fluid retention in a population with compromised cardiac function pushed some patients toward symptomatic heart failure. The Data Safety Monitoring Board determined the risk-benefit profile was unfavorable.[4]
For younger, healthier users, the edema is typically cosmetic rather than dangerous: puffy face, swollen fingers, and a few pounds of water weight gain. But the hip fracture trial demonstrates that in vulnerable populations, the same mechanism can produce serious cardiovascular consequences. Anyone with pre-existing heart disease, hypertension, or kidney dysfunction faces elevated risk from sustained GH-mediated fluid retention.
Appetite stimulation: a feature, not a bug
MK-677 works by mimicking ghrelin, the "hunger hormone." The ghrelin receptor (GHS-R1a) serves dual roles: it stimulates growth hormone release from the pituitary and it stimulates appetite through hypothalamic pathways. MK-677 activates both. Appetite stimulation is not a separable side effect; it is baked into the drug's mechanism of action.
Murphy et al. (1998) demonstrated that MK-677 reversed diet-induced catabolism in healthy volunteers placed on caloric restriction. The appetite-stimulating effect was robust enough to partially counteract the caloric deficit, which limits its utility for anyone trying to use it during a cut or caloric restriction phase.[3]
The appetite increase is most pronounced in the first few weeks of treatment and tends to moderate over time, but it does not disappear. In the Nass et al. trial, increased appetite was noted throughout the 12-month study period. This pattern mirrors what is seen with GHRP-6, which causes intense hunger through the same ghrelin receptor mechanism. Ipamorelin was developed specifically to activate GH release with less appetite stimulation, reflecting the clinical limitation that MK-677's hunger effect imposes.
The Svensson et al. (1998) data adds a paradox: despite increased appetite, MK-677-treated obese subjects gained fat-free mass while losing some visceral fat. The drug's metabolic effects partially redirected nutrient partitioning toward lean tissue, but total caloric intake still rose.[2]
Effects on sleep architecture
Not all of MK-677's effects are adverse. Copinschi et al. (1997) conducted a study on sleep quality during MK-677 treatment and found that 25 mg daily increased the duration of stage IV (deep) sleep by approximately 50% and increased REM sleep duration by about 20% in young healthy subjects. These improvements in sleep architecture are consistent with the known sleep-promoting effects of growth hormone pulses during the night.[8]
The earlier Copinschi et al. (1996) study confirmed that MK-677 amplified the nocturnal GH pulse pattern, with peak GH levels occurring during the same sleep stages where they normally appear, but at higher amplitude.[9] This sleep effect is one of the primary reasons MK-677 users report subjective benefit, and it drives interest in the compound for sleep quality research. Whether the sleep benefits justify the metabolic costs is an open question.
Body composition: the nuanced picture
MK-677 consistently increases fat-free mass (FFM). In the Nass et al. (2008) trial, FFM increased by approximately 1.1 kg over 12 months. In the Svensson et al. (1998) trial, FFM increased after just 2 months. Cardaci et al. (2022) confirmed body composition changes in recreational MK-677 users, finding shifts consistent with GH/IGF-1 axis activation.[6]
But the Nass et al. finding that matters most for the side effect discussion: despite increasing FFM, MK-677 did not improve functional performance. Grip strength, knee extension strength, and stair climbing did not improve compared to placebo. This dissociation between mass and function suggests that some of the FFM gain was water retention rather than contractile muscle tissue.[1]
This distinction is critical. Users who interpret weight gain on MK-677 as muscle growth may be partially measuring fluid shifts. The broader question of IGF-1 elevation and its risks adds another dimension: chronically elevated IGF-1 is associated with increased cancer risk in epidemiological studies, though a causal link in the context of MK-677 has not been established.
The Alzheimer's trial and the CHF signal
Two trials provide cautionary data about MK-677 in elderly and vulnerable populations.
Sevigny et al. (2008) tested MK-677 for 12 months in patients with mild-to-moderate Alzheimer's disease. Despite raising IGF-1 levels, MK-677 produced no cognitive benefit. The clinical progression of AD was identical between treatment and placebo groups. Side effects included worsened glucose control in diabetic participants and increased appetite.[7]
Adunsky et al. (2011) tested MK-677 in 123 patients recovering from hip fracture, a population where both sarcopenia and GH deficiency are common. The trial aimed to show that raising GH/IGF-1 levels would accelerate functional recovery. It failed. MK-677-treated patients showed no improvement in functional endpoints compared to placebo. The trial was stopped early after the Data Safety Monitoring Board identified signals of congestive heart failure. The combination of fluid retention, decreased insulin sensitivity, and compromised cardiovascular reserve in this frail elderly population produced an unacceptable risk profile.[4]
MK-677 versus peptide-based GH secretagogues
Understanding MK-677's side effects requires context: how do they compare to peptide-based alternatives? MK-677 is not a peptide. It is a non-peptide small molecule that mimics ghrelin. Peptide growth hormone secretagogues like GHRP-2 and GHRP-6 and sermorelin share some overlapping side effects but differ in important ways.
Sigalos and Pastuszak (2018) reviewed the safety and efficacy of growth hormone secretagogues as a class. Their analysis concluded that MK-677 reliably elevates GH and IGF-1 but that metabolic side effects, particularly insulin resistance, limit its clinical utility. Peptide-based secretagogues that act through the GHRH receptor (like CJC-1295) rather than the ghrelin receptor tend to produce less appetite stimulation, though they still carry the GH-mediated effects on glucose metabolism.[5]
MK-677's oral bioavailability, which is its primary commercial advantage, means it provides 24-hour GHS-R1a activation with a single daily dose. Peptide secretagogues, which require injection and have shorter half-lives, produce more pulsatile GH elevation that may be more physiological. Whether pulsatile dosing reduces metabolic side effects compared to sustained receptor activation has not been tested in a head-to-head comparison.
Regulatory status and unapproved use
MK-677 remains an investigational compound. It has not been approved by the FDA for any indication. Despite this, it is widely available through research chemical suppliers and online vendors, and it is used recreationally at doses of 10-25 mg daily for body composition and sleep quality purposes.
The gap between clinical evidence and recreational use is substantial. Trial data comes from doses of 25 mg daily in controlled settings with regular blood monitoring. Recreational users often self-administer without baseline metabolic testing, glucose monitoring, or medical supervision. The metabolic effects documented in clinical trials, particularly the glucose and insulin changes, can progress silently until they manifest as frank diabetes or cardiovascular symptoms.
The Bottom Line
MK-677's side effect profile is well characterized by clinical trial data spanning nearly three decades. Insulin resistance and glucose dysregulation are the most clinically significant effects, documented across every major study. Water retention is common and usually benign in healthy populations but contributed to congestive heart failure signals in the hip fracture recovery trial. Appetite stimulation is inherent to the ghrelin receptor mechanism and cannot be separated from the drug's GH-releasing activity. Despite consistently increasing fat-free mass, MK-677 has not demonstrated functional strength improvements in any randomized trial, and two large trials in elderly populations (Alzheimer's and hip fracture) failed to show clinical benefit while revealing safety concerns.